Comparison of Concentration of Epitheliotrophic Growth Factors in Platelet-Rich Plasma and Autologous Serum and the Efficacy in Dry Eye Disease

Phase 1

Recruiting

• Conditions: Dry eye diseaseConcentration of epitheliotrophic growth factors in PRP and ASEfficacy in treatment of DED of PRP and ASStability of epitheliotrophic growth factors in PRP and AS; epitheliotrophic growth factor; autologous serum; platelet- rich plasma; efficacy; concentration; stability; dry eye disease

• Registration Number: TCTR20191119001
• Lead Sponsor: Siriraj Research Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-11-19
• Study Completion: 2020-06-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

The patients will be included to the study, when they meet all of the criteria Dry Eye Disease Diagnostic Test Battery: (modified from TFOS DEWS II; Diagnostic Methodology report)
OSDI (Ocular Surface Disease Index) ≥ 13
Diagnostic Testing (Homeostasis Markers)
Fluorescein Breakup Time < 10 seconds or
Ocular Surface Staining:
- > 5 corneal spots or
- > 9 conjunctival spotsor
- Lid margin (≥ 2mm length & ≥ 25% width)

Exclusion Criteria

Taking immunosuppressive drugs
AIDs patients or other immunodeficiency conditions
Having serious systemic underlying diseases
Pregnant women
Unequal severity of dry eye disease between two eyes

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Concentration of epitheliotrophic growth factors in Platelet-Rich Plasma and Autologous Serum At the time of intervention Enzyme-linked immunosorbent assay (ELISA) according to the manufacturers’ instruction

Secondary Outcome Measures

Name	Time	Method
The efficacy of PRP and AS in DED 1 month Dry eye ocular symptoms (OSDI score and Dry Eye Questionnaire, used in The Osaka Study16) and signs(,the stability of epitheliotrophic growth factors in PRP and AS Baselline, 1 month, 6 months enzyme-linked immunosorbent assay (ELISA) according to the manufacturers’ instruction at 1 week, 1